Global GLP-1 Analogues Supply, Demand and Key Producers, 2023-2029

Global GLP-1 Analogues Supply, Demand and Key Producers, 2023-2029

The global GLP-1 Analogues market size is expected to reach $ 3889 million by 2029, rising at a market growth of 6.5% CAGR during the forecast period (2023-2029).

GLP-1 analogues are a class of medications used in the treatment of type 2 diabetes. They mimic the effects of glucagon-like peptide 1 (GLP-1), which is a hormone produced by the gut that helps regulate blood sugar levels by stimulating insulin secretion and reducing glucagon secretion.

This report studies the global GLP-1 Analogues production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for GLP-1 Analogues, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of GLP-1 Analogues that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global GLP-1 Analogues total production and demand, 2018-2029, (K Units)

Global GLP-1 Analogues total production value, 2018-2029, (USD Million)

Global GLP-1 Analogues production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global GLP-1 Analogues consumption by region & country, CAGR, 2018-2029 & (K Units)

U.S. VS China: GLP-1 Analogues domestic production, consumption, key domestic manufacturers and share

Global GLP-1 Analogues production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)

Global GLP-1 Analogues production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global GLP-1 Analogues production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)

This reports profiles key players in the global GLP-1 Analogues market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Jiangsu Hansoh Pharmaceutical and Shanghai Benemae Pharmaceutical, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World GLP-1 Analogues market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global GLP-1 Analogues Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global GLP-1 Analogues Market, Segmentation by Type
Exenatide
Liraglutide
Semaglutide
Dulaglutide
Other

Global GLP-1 Analogues Market, Segmentation by Application
Hospital
Clinic
Other

Companies Profiled:
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Jiangsu Hansoh Pharmaceutical
Shanghai Benemae Pharmaceutical

Key Questions Answered

1. How big is the global GLP-1 Analogues market?

2. What is the demand of the global GLP-1 Analogues market?

3. What is the year over year growth of the global GLP-1 Analogues market?

4. What is the production and production value of the global GLP-1 Analogues market?

5. Who are the key producers in the global GLP-1 Analogues market?

6. What are the growth factors driving the market demand?